Clinical Trials (Clinical Perspective)

  • Salvatore Cucchiara
  • Osvaldo Borrelli


Ulcerative Colitis Crohn Disease Pyoderma Gangrenosum Height Velocity Physician Global Assessment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Griffiths AM. Specificities of inflammatory bowel disease. Best Pract & Res Clin Gastroenterol 2004;18:509–523.CrossRefGoogle Scholar
  2. 2.
    Carvalho RS, Abandom V, Dilworth HP, et al. Indeterminate colitis:a significant subgroup of pediatric IBD. Inflamm Bowel Dis 2006;12:258–262.PubMedCrossRefGoogle Scholar
  3. 3.
    Griffiths AM, Otley AR, Hyams J. et al. A review of activity indices and end points for clinical trials in children with Crohn disease. Inflamm Bowel Dis 2005;11:185–196.PubMedCrossRefGoogle Scholar
  4. 4.
    Sands BE, Abreu MT, Ferry G et al. Design issues and outcomes in IBD clinical trials. Inflamm Bowel Dis 2005;11:S22–S28.PubMedCrossRefGoogle Scholar
  5. 5.
    Pappa HM, Semrin G, Walker TR, Grand RJ. Pediatric inflammatory bowel disease. Curr Opin Gastroenterol 2004;20:333–340.PubMedCrossRefGoogle Scholar
  6. 6.
    Crofton PM, Kelnar CJH. Bone and collagen markers in pediatric practice. Int J Clin Pract 1998;52: 557–565.PubMedGoogle Scholar
  7. 7.
    Kim SC, Ferry GD. Inflammatory bowel disease in early childhood and adolescence: special considerations. Gastroenterology 2004;126:1550–1560.PubMedCrossRefGoogle Scholar
  8. 8.
    Best W, Becktel J, Singleton J et al. Development of a Crohn disease activity index. Gastroenterology 1976;70:439–444.PubMedGoogle Scholar
  9. 9.
    Hyams J, Ferry G, Mandel F, et al. Development and validation of a pediatric Crohn disease activity index. J Pediatr Gastroenterol Nutr 1991;12:439–447.PubMedGoogle Scholar
  10. 10.
    Kundhal PS, Critch JN, Zachos M, et al. Pediatric Crohn disease activity index:responsive to short-term change. J Pediatr Gastroenterol Nutr 2003;36:83–89.PubMedCrossRefGoogle Scholar
  11. 11.
    Otley A, Loonen H, Parekh N, et al. Assessing activity of pediatric Crohn disease:which index to use? Gastroenterology 1999;116:527–531.PubMedCrossRefGoogle Scholar
  12. 12.
    Hyams J, Markowitz J, Otley A, et al. Evaluation of the pediatric Crohn disease activity index: usefulness in the practice setting. J Pediatr Gastroenterol Nutr 2004;39 (Suppl):0712.Google Scholar
  13. 13.
    Hyams J, Markowitz J, Otley A, et al. Evaluation of the pediatric Crohn disease activity index:a prospective multicenter experience. J Pediatr Gastroenterol Nutr 2005;41:416–421.PubMedCrossRefGoogle Scholar
  14. 14.
    Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. BMJ 1955;2:1041–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisone given as single or multiple daily doses for active ulcerative colitis. Scand J Gastroenterol 1978;13:833–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in treatment of active ulcerative colitis: a randomised trial. BMJ 1989;298:82–6.PubMedGoogle Scholar
  17. 17.
    Baron JH, Conell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearance in proctocolitis. BMJ 1964;1:89–92.PubMedGoogle Scholar
  18. 18.
    Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderate active ulcerative colitis. A randomised study. N Engl J Med 1987;317:1625–9.PubMedCrossRefGoogle Scholar
  19. 19.
    D’Haens G, Hlavaty T. Advances in medical therapy for Crohn disease. Curr Gastroenterol Rep 2004;6:496–505.PubMedCrossRefGoogle Scholar
  20. 20.
    Mamula P, Markowitz JE, Baldassano RN. Inflammatory bowel disease in early childhood and adolescence: special considerations. Gastroenterol Clin North Am 2003;32:867–995.CrossRefGoogle Scholar
  21. 21.
    Arnott ID, Watts D, Ghosh S. Review article:is clinical remission the optimum therapeutic goal in the treatment of Crohn disease? Aliment Pharmacol Ther 2002;16:857–67.PubMedCrossRefGoogle Scholar
  22. 22.
    Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn disease. Gastrointest Endosc 2006;63:433–442.PubMedCrossRefGoogle Scholar
  23. 23.
    Griffiths AM, Nicholas D, Smith C, et al. Development of a quality-of-life index for pediatric inflammatory bowel disease: dealing with differences related to age and IBD type. J Pediatr Gastroenterol Nutr 1999;28:S46–S52.PubMedCrossRefGoogle Scholar
  24. 24.
    Otley A, Smith C, Nicholas D, et al. The IMPACT questionnaire: a valid measure of health-related quality of life in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2002;35:557–563.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Salvatore Cucchiara
    • 1
  • Osvaldo Borrelli
  1. 1.Division of Pediatric and Liver Unit, Head, Pediatric Inflammatory Bowel Disease Center, DirectorUniversity Hospital Umberto I, University of Rome “La Sapienza”Viale Regina Elena 324 – 00161 RomeItaly

Personalised recommendations